BioSpace News Archive

Beckman Coulter, a clinical diagnostics leader, today announced the launch of its Access SARS-CoV-2 Immunoglobulin M (IgM) assay. The new IgM antibody test demonstrated 99.9% specificity against 1,400 negative samples and 98.3% sensitivity at 15-30 days post-symptom onset.

Indee Labs announces a grant award from the National Institute of Allergy and Infectious Diseases to develop the µVS Delivery SystemTM for modified regulatory T cells

Asklepios BioPharmaceutical, Inc. (AskBio), a leading, clinical-stage adeno-associated virus (AAV) gene therapy company, today announced that its president and chief scientific officer, Jude Samulski, PhD, has been honored as one of the Triangle Business Journal’s (TBJ) 2020 Life Sciences Award winners. The award recognizes individuals and research organizations at the forefront of innovation in the growing Triangle-area life

Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, announced today that it has been awarded a Top Workplaces 2020 honor by the Bay Area News Group for the seventh consecutive year. The annual award is based solely on employee feedback gathered through an anonymous, third-party survey. “I am so proud

Ortho Regenerative Technologies Inc., an emerging orthobiologics company focused on the development of novel soft tissue repair regenerative technologies, announced the closing of a non-brokered $2.5 million private placement of units.

Jason Baum, Ph.D., Joins as Vice President, Head of Translational Medicine Christine Granfield Named Vice President, Head of Regulatory Affairs and Quality

Focus on Yumanity’s lead clinical program in Parkinson’s disease and transformative pipeline of disease-modifying treatments for neurogenerative disorders

$98.7M financing, development fees and commercial milestone commitments accelerate the development and commercialization of One Drop’s digital health platform and data-driven predictive capabilities across multiple therapeutic areas

Humanigen, Inc. announced the appointment of Edward P. Jordan, MBA, to Chief Commercial Officer, a new role that will report to Dr. Cameron Durrant, Chief Executive Officer of Humanigen, effective immediately.

Prelude Therapeutics, a privately-held, clinical-stage precision oncology company, announced that it has completed a $50 million Series C financing round led by Prelude’s two existing institutional investors, including OrbiMed Advisors LLC, and a new investor, Fidelity Management & Research Company LLC.